An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment

作者：Zhu, Wenhui; Xu, Hua; Ma, Jing; Guo, Jianming; Xue, Wei; Gu, Baojun; Sheng, Lu; Yao, Xudong; Sun, Fukang; Gong, Jian; Qiu, Weiliang; Ding, Qiang; Jiang, Haowen^*

来源：Urologia Internationalis, 2017, 98(1): 79-84.

DOI：10.1159/000448691

• Prostate cancer
• Metformin
• Androgen deprivation therapy
• C-peptide
• Insulin
• Body weight

Purpose: The study aimed to evaluate the effects of metformin on insulin, C-peptide and body weight in Chinese men undergoing androgen deprivation therapy (ADT). Methods: Between March 2013 and June 2014, 62 newly diagnosed patients of prostate cancer (PCa) due to receive ADT were recruited from 7 hospitals in Shanghai. Patients were randomized to respectively receive ADT (n = 31) and ADT + metformin (n = 31) for 6 months. Fasting and postprandial serum levels of insulin and C-peptide, blood glucose, prostate specific antigen, body mass index (BMI) and waist circumference (WC) were measured at the beginning and end of 6-month treatment. Results: Baseline characteristics were comparable between the 2 groups. Controlling for baseline levels, the ADT group had significantly higher levels of fasting glucose (p = 0.01) and higher WC (p = 0.04) than the ADT+ metformin group. The levels of insulin, C-peptide and BMI did not differ significantly. Conclusions: Metformin may be potentially efficient as a concomitant therapy on patients with PCa undergoing androgen deprivation treatment.

• 出版日期2017
• 单位同济大学; 上海交通大学; 复旦大学; 上海市闵行区中心医院